Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · The Lancet · 556 citations
https://doi.org/10.1016/s0140-6736(21)00149-5
M
Mary Edmondson
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
47
Papers
3.2K
Citations
19
h-index
21
i10-index
Mary Edmondson is an academic researcher. The author has contributed to research in topics: Genetic Neurodegenerative Diseases & COVID-19 Clinical Research Studies & SARS-CoV-2 and COVID-19 Research. The author has an h-index of 19, co-authored 40 publications.
Papers by this author
worksConvalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · The Lancet · 516 citations
https://doi.org/10.1016/s0140-6736(21)00897-7
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · The Lancet · 320 citations
https://doi.org/10.1016/s0140-6736(22)01109-6
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · The Lancet · 289 citations
https://doi.org/10.1016/s0140-6736(21)01825-0
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · The Lancet Diabetes & Endocrinology · 36 citations
https://doi.org/10.1016/s2213-8587(23)00253-x
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · The Lancet Diabetes & Endocrinology · 36 citations
https://doi.org/10.1016/s2213-8587(23)00253-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat